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Mycobacterial Infection after Intravesical Bacillus Calmette-Guërin 
Treatment for Bladder Cancer: A Case Report
Chang-Hun Park, M.D., Mi Ae Jang, M.D., Yoon Hee Ahn, M.T., Yu-Yean Hwang, M.T., Chang-Seok Ki, M.D., 
and Nam Yong Lee, M.D.
Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Bacillus Calmette-Guërin (BCG) has been traditionally used as a vaccine against tuberculosis. Further, intravesical administration of 
BCG has been shown to be effective in treating bladder cancer. Although BCG contains a live attenuated strain of Mycobacterium 
bovis, complications such as M. bovis BCG infection caused by BCG administration are extremely rare. Here, we report a case of BCG 
infection occurring after intravesical BCG therapy. A 67-yr-old man presented with azotemia and weight loss. He had been diag-
nosed with bladder cancer 4 yr back, and had undergone transurethral resection of the bladder tumor and intravesical BCG (Tice 
strain) therapy at that time. An acid-fast bacterial strain was isolated from his urine sample. We did not detect Mycobacterium tuber-
culosis protein 64 (MPT-64) antigen in the isolates obtained from his sample, and multiplex PCR and PCR-reverse blot hybridization 
assay indicated that the isolate was a member of the M. tuberculosis complex, but was not M. tuberculosis. Finally, sequence analysis 
of 16S ribosomal RNA and DNA gyrase, subunit B (gyrB) suggested that the organism was M. bovis or M. bovis BCG. Although we 
could not confirm that M. bovis BCG was the causative agent, the results of the 3 molecular methods and the MPT-64 antigen assay 
suggest this finding. This is an important finding, especially because M. bovis BCG cannot be identified using common commercial 
molecular genetics tools.
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INTRODUCTION
Bacillus Calmette-Guërin (BCG) has been traditionally 
used as a vaccine against tuberculosis. Further, intravesical 
administration of BCG has been shown to be effective in 
treating bladder cancer [1]. BCG contains a live attenuated 
strain of Mycobacterium bovis (M. bovis BCG); however, 
complications after bladder instillation of BCG are extreme-
ly rare [2]. The few complications reported to date include 
high temperature followed by hematuria or granulomatous 
prostatitis, epididymo-orchitis, urethral obstruction, and 
systemic disease followed by dissemination of bacteria into 
other organs [3-5]. Here, we report a case of a M. bovis BCG 
infection that occurred after intravesical BCG therapy for 
bladder cancer. 
CASE REPORT
A 67-yr-old male patient presented at our institution with 
azotemia. Three months before consulting our institute, he 
had visited a local clinic because he had been experiencing 
general weakness and poor oral intake. Biochemical and ul-
trasonographic examinations performed at the clinic, re-
vealed elevated serum creatinine and obstruction of the left 
ureter, respectively. Other than a weight loss of 10 kg, the 
patient did not show any clinical features associated with M. 
bovis BCG infection, such as fever, chills, and night sweats. 
Right antegrade pyelography showed mild hydroureterone-
phrosis with focal stenosis in the ureteropelvic junction. 
The patient’s history included diabetes mellitus and chronic 
renal failure for which he had received intermittent hemo-
dialysis. He had been diagnosed with bladder cancer 4 yr 
back, and he had undergone transurethral resection of the 198     www.kjlm.org
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bladder tumor (TUR-B), which was immediately followed 
by intravesical BCG therapy (Tice strain BCG; 12.5 mg of 
intravesical BCG was injected through a catheter into the 
bladder once every week for 6 weeks). A year later, another 
TUR-B was performed because atypical cells were observed 
in his urine, and a histological examination of his bladder 
indicated chronic granulomatous inflammation. Although, 
a diagnostic work-up for mycobacterial infections was not 
performed at that time, mycobacterial infection was sug-
gested and the patient was administered isoniazid (300 mg/
day), rifampicin (600 mg/day), ethambutol (800 mg/day), 
pyrazinamide (1 g/day), and pyridoxine (50 mg/day) for 3 
months.
Laboratory testing performed upon admission at our in-
stitute yielded the following findings: proteinuria and py-
uria in urinalysis, no microorganisms in Gram’s staining of 
the urine sample, and acid-fast bacteria (AFB) in AFB 
staining of the voided urine. Mycobacteria were isolated by 
inoculating the patient’s urine in Ogawa medium (solid 
egg-based medium) and by using the BACTEC MGIT 960 
mycobacterial detection system (BD, Franklin Lakes, NJ, 
USA). The colony morphology and staining results of the 
isolated microorganism are shown in Fig. 1.
To identify the mycobacterial species present in the pa-
tient’s samples, the Mycobacterium tuberculosis protein 64 
(MPT-64) antigen assay, multiplex-PCR, and PCR-reverse 
blot hybridization assay (REBA) were performed. The MPT-
64 antigen detection assay was performed using samples ob-
tained from liquid cultures by using the TB Ag MPT64 
Rapid kit (SD, Yongin, Korea). Multiplex-PCR and PCR-
REBA were performed using the MTB-ID® V3 assay system 
(M&D, Wonju, Korea) and the REBA Myco-ID® assay sys-
tem (M&D), respectively. The MPT-64 antigen is typically 
detected in specimens containing members of the M. tuber-
culosis (MTB) complex, which includes M. tuberculosis, M. 
bovis, Mycobacterium microti, Mycobacterium africanum, 
and other mycobacterial species. However, we did not detect 
this antigen in specimens from this patient. Multiplex-PCR 
allows differentiation of M. tuberculosis and mycobacterium 
other than tuberculosis (MOTT) on the basis of the band 
sizes (204 bp and 360 bp, respectively). In this study, we ob-
served a band of 360 bp (Fig. 2). PCR-REBA allows differen-
tiation of the MTB complex and non-tuberculous mycobac-
teria (NTM) on the basis of the band position on a gel strip 
(refer to http://www.mndkorea.co.kr for details). In this case, 
the band pattern obtained after PCR-REBA suggested that 
the isolate belongs to the MTB complex. Thus, on the basis 
of the results obtained after performing multiplex-PCR and 
PCR-REBA, the microorganism isolated from the patient’s 
samples was suspected to be a member of the MTB com-
plex, but not M. tuberculosis. However, the 2 PCR methods 
and the assay for MPT-64 antigen yielded different results.
Hence, in order to identify the causative agent we perfor-
med sequence analysis of 16S ribosomal RNA (16S rRNA) 
and DNA gyrase, subunit B (gyrB). For sequence analysis, 
DNA was isolated using the MagNa Pure LC Total Nucleic 
Acid Isolation Kit (Roche, Mannheim, Germany) as per the 
manufacturer’s instructions. PCR for 16S rRNA and gyrB 
gene was performed in an ABI 9700 Thermal Cycler (Ap-
plied Biosystems, Foster City, CA, USA) using the appropri-
ate primer sets suggested by the CLSI [6] and Nakajima et 
al. [7]. Bi-directional sequence analysis was performed us-
ing the ABI Pri-sm BigDye Terminator Cycle Sequencing 
Ready Reaction kit (Applied Biosystems) on an ABI Prism 
3730 Genetic Analyzer (Applied Biosystems). Sequence 
A B
Fig. 1. Colony morphology on solid medium (A) and cord formation by acid-
fast bacillus (B) (Ziehl-Neelsen stain,×1,000). The presence of cords is 
known to be a criterion for presumptive identification of the Mycobacterium 
tuberculosis complex.
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Fig. 2. Multiplex-PCR to identify the isolate. Products of the multiplex-PCR 
performed using DNA from the isolates were separated on a 2.0% agarose 
gel using electrophoresis, and the gel was stained with ethidium bromide. 
The bands for the isolates (S1-S3 and L1-L3) corresponded to that for NTM. 
IC, internal control (660 bp); NC, negative control; NTM, control non-tubercu-
lous mycobacteria; MTB, control Mycobacterium tuberculosis; S1-S3, isolates 
from solid media; L1-L3, isolates from liquid media; M, molecular markers.Park C-H, et al.  •  Mycobacterial Infection after Intravesical BCG Therapy
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analysis showed that the 16S rRNA (696 bp) of the isolate 
had 100% similarity with that of M. bovis BCG (GenBank 
accession no. GU142938), M. tuberculosis (GenBank acces-
sion no. GU142936), M. caprae (GenBank accession no. 
NR028879), M. africanum (GenBank accession no. NR-
025238), M. microti (GenBank accession no. NR025234), 
and M. bovis (GenBank accession no. BX248338). The anal-
ysis of the gyrB gene (479 bp) revealed a 100% similarity 
between the sequence of the isolate and the sequence of M. 
bovis BCG (GenBank accession no. AM408590, AP010918) 
and M. bovis (GenBank accession no. BX248334).
DISCUSSION
Complications caused by M. bovis BCG administration 
have been rarely reported. A retrospective study by Lamm 
et al. [2] suggests that local adverse effects, including cysti-
tis, fever, hematuria, and prostatitis, are the most frequent 
complications, whereas extravesical complications are rare. 
Other local adverse effects include bladder contractures, ep-
ididymo-orchitis, ureteral obstruction, and renal abscesses 
with or without fistula formation. Although this patient did 
not show any significant symptoms, the laboratory findings 
indicated renal dysfunction and the results of right ante-
grade pyelography indicated mild ureteral stenosis. Myco-
bacterial infections occurring after intravesical administra-
tion of BCG have been rarely reported from Korea. Most of 
the cases reported to date were based on the pathological 
findings, and to our knowledge, there are no reports of cases 
in which the causative species of mycobacterium has been 
identified. To diagnose a mycobacterial infection, Nam et al. 
[8] and Jeon et al. [9] examined infected tissue showing 
chronic granulomatous inflammation with caseous necro-
sis. Lee et al. [10] and Kim et al. [11] used AFB staining to 
determine whether an infection was mycobacterial in na-
ture. Son et al. [12] used PCR to determine whether an in-
fection was caused by a mycobacterium but they were un-
successful. Recently, Kim et al. [13] reported that a molecu-
lar method using multiplex PCR for the region of difference 
1 (RD1), RD8, and RD14 can be used to confirm BCG in-
fection. We hypothesized that M. bovis BCG was the caus-
ative agent in this case and attempted to identify this organ-
ism by mycobacterial cultivation, MPT-64 antigen assay, 
and other molecular methods. 
MPT-64 is a 26-kDa secretory protein produced by M. tu-
berculosis, and the initially purified protein was a homolog 
from M. bovis BCG, MPB-64 [14, 15]. The MPT-64 antigen 
assay can specifically detect the MPT-64 antigen secreted by 
the tuberculosis-causing bacteria. Usually, detection of MPT-
64 antigen in this assay is suggestive of the presence of an or-
ganism of the MTB complex, which includes M. tuberculosis, 
M. bovis, M. microti, and M. africanum. However, some 
strains of M. bovis BCG, such as Copenhagen, Glaxo, Pas-
teur, and Tice, do not express the MPB-64 gene [16, 17]. The 
absence of the MPT-64 antigen in our patient can be ex-
plained by the fact that the Tice BCG strain was injected into 
the patient’s bladder. The multiplex-PCR and PCR-REBA 
methods used were not helpful in confirming whether the 
causative agent was M. bovis because these methods could 
not distinguish M. bovis from other members of the MTB 
complexes (Table 1). The sequence analysis of 16S rRNA and 
gyrB gene was useful in distinguishing the members of the 
MTB complex, but this method had a limited ability in 
clearly distinguishing between the M. bovis and M. bovis 
BCG strains.
Although we could not confirm that M. bovis BCG was 
the causative agent in this case, the methods employed, 
which included detection of MPT-64 antigen, PCR, and se-
quence analysis of 16S rRNA and gyrB gene, suggest that 
the causative agent is the Tice strain of M. bovis BCG. This 
is an important finding since M. bovis BCG cannot be iden-
tified using common commercial molecular genetics tools. 
The patient was treated with anti-mycobacterial agents for 3 
months. Subsequently, AFB staining and mycobacterial cul-
ture were performed to detect any residual mycobacterial in-
fection, but no mycobacteria were seen in both assessments.
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